Tesamorelin
Tesamorelin and the location of fat
A waist measurement cannot show where fat is stored. Tesamorelin's clinical story takes place around abdominal organs and inside the liver.
Abdominal fat distribution with HIV
Visceral fat sits within the abdominal cavity around internal organs. That location gives the tesamorelin fat trial its subject: adults with HIV receiving antiretroviral treatment who had abdominal fat accumulation.
Belly fat is a convenient phrase, and I think convenience has done this molecule a disservice. It encourages a mental picture of a smaller silhouette, while the trial addresses a particular fat compartment in people with a particular medical history. Fat beneath the skin is a separate compartment.
The distinction also explains tesamorelin's approved use: reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. Its U.S. approval dates to 2010. General weight loss, cosmetic waist reduction and treatment of liver disease unrelated to HIV fall outside that approval.
JAMA: abdominal and hepatic fat
The six-month randomized trial enrolled 50 adults with HIV taking antiretroviral therapy. Tesamorelin reduced visceral fat and liver fat compared with placebo. Both the tissue and the clinical setting are explicit, which makes the result useful beyond the general phrase fat loss.
A 2026 meta-analysis of five randomized trials in HIV-associated lipodystrophy also found reductions in visceral fat, trunk fat and hepatic fat fraction, alongside increased lean body mass. Lean mass includes water and organs as well as muscle, so the finding alone cannot establish a muscle-building effect.
The pooled trials reported no serious adverse events. That describes what those trials reported; limited follow-up leaves longer-term safety questions open. Their combined results also remain evidence about HIV-associated lipodystrophy.
Tesamorelin withdrawal
The 52-week study reported sustained visceral-fat reduction of -18%. Fat reaccumulated after treatment was discontinued. Glucose changes over 52 weeks were not clinically significant.
I struggle to call a fat reduction complete when visceral fat returns after withdrawal. Continued treatment and treatment withdrawal are different parts of the clinical story. A photograph taken at the end of treatment would miss what happened afterward.
That observation does not tell an individual whether to start, continue or stop treatment. It tells us that the trial's fat reduction was contingent, and it makes durability a serious question alongside the amount of fat lost.
Growth hormone and safety
Tesamorelin stimulates the pituitary to release growth hormone, which raises the growth factor IGF-1. In a two-week study of 13 healthy men, overnight growth hormone rose and IGF-1 increased by 181 micrograms per liter. Fasting glucose and insulin-stimulated glucose uptake showed no significant change. Those men were a different population from the fat-trial participants.
Growth-hormone stimulation brings concerns about blood sugar and unwanted tissue growth, including the importance of existing cancer when considering treatment. A short mechanistic study cannot settle years of exposure. The LiverTox assessment judged tesamorelin an unlikely cause of clinically apparent liver injury and noted no attributable reported cases; that is a finding about liver injury specifically.
TH9507 is an older research name for tesamorelin, and acetate names the salt used in the supplied medicine. Neither adds a second body of clinical results. The comparison page sets this history beside CJC-1295, whose growth-hormone action has a much smaller human evidence base.